262 related articles for article (PubMed ID: 28548706)
1. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
[TBL] [Abstract][Full Text] [Related]
2. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Raney RB; Walterhouse DO; Meza JL; Andrassy RJ; Breneman JC; Crist WM; Maurer HM; Meyer WH; Parham DM; Anderson JR
J Clin Oncol; 2011 Apr; 29(10):1312-8. PubMed ID: 21357783
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan A; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
Cancer; 2017 Jun; 123(12):2368-2375. PubMed ID: 28211936
[TBL] [Abstract][Full Text] [Related]
4. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Walterhouse DO; Pappo AS; Meza JL; Breneman JC; Hayes-Jordan AA; Parham DM; Cripe TP; Anderson JR; Meyer WH; Hawkins DS
J Clin Oncol; 2014 Nov; 32(31):3547-52. PubMed ID: 25267746
[TBL] [Abstract][Full Text] [Related]
5. Local control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 study.
Breneman J; Meza J; Donaldson SS; Raney RB; Wolden S; Michalski J; Laurie F; Rodeberg DA; Meyer W; Walterhouse D; Hawkins DS
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):720-6. PubMed ID: 22104356
[TBL] [Abstract][Full Text] [Related]
6. Outcome of patients with localized orbital sarcoma who relapsed following treatment on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III and -IV, 1984-1997: a report from the Children's Oncology Group.
Raney B; Huh W; Hawkins D; Hayes-Jordan A; Million L; Rodeberg D; Teot L; Anderson J;
Pediatr Blood Cancer; 2013 Mar; 60(3):371-6. PubMed ID: 22961750
[TBL] [Abstract][Full Text] [Related]
7. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM; Anderson JR; Meza JL; Fryer C; Raney RB; Ruymann FB; Breneman J; Qualman SJ; Wiener E; Wharam M; Lobe T; Webber B; Maurer HM; Donaldson SS
J Clin Oncol; 2001 Jun; 19(12):3091-102. PubMed ID: 11408506
[TBL] [Abstract][Full Text] [Related]
8. 45 GyRBE for group III orbital embryonal rhabdomyosarcoma.
Indelicato DJ; Rotondo RL; Mailhot Vega RB; Uezono H; Bradfield S; Agarwal V; Hol ML; Bradley JA
Acta Oncol; 2019 Oct; 58(10):1404-1409. PubMed ID: 31530120
[No Abstract] [Full Text] [Related]
9. Current status of treatment for pediatric rhabdomyosarcoma in the USA and Japan.
Hosoi H
Pediatr Int; 2016 Feb; 58(2):81-7. PubMed ID: 26646016
[TBL] [Abstract][Full Text] [Related]
10. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Hawkins DS; Chi YY; Anderson JR; Tian J; Arndt CAS; Bomgaars L; Donaldson SS; Hayes-Jordan A; Mascarenhas L; McCarville MB; McCune JS; McCowage G; Million L; Morris CD; Parham DM; Rodeberg DA; Rudzinski ER; Shnorhavorian M; Spunt SL; Skapek SX; Teot LA; Wolden S; Yock TI; Meyer WH
J Clin Oncol; 2018 Sep; 36(27):2770-2777. PubMed ID: 30091945
[TBL] [Abstract][Full Text] [Related]
11. Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: A Report From the Children's Oncology Group.
Wolden SL; Lyden ER; Arndt CA; Hawkins DS; Anderson JR; Rodeberg DA; Morris CD; Donaldson SS
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1071-6. PubMed ID: 26581144
[TBL] [Abstract][Full Text] [Related]
12. Local control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.
Walterhouse DO; Meza JL; Breneman JC; Donaldson SS; Hayes-Jordan A; Pappo AS; Arndt C; Raney RB; Meyer WH; Hawkins DS
Pediatr Blood Cancer; 2011 Jul; 57(1):76-83. PubMed ID: 21298768
[TBL] [Abstract][Full Text] [Related]
13. [Orbital rhabdomyosarcoma: difficulties with European treatment protocol].
Olivier Pascual N; Calvo JM; Abelairas Gómez JM
Arch Soc Esp Oftalmol; 2005 Jun; 80(6):331-8. PubMed ID: 15986273
[TBL] [Abstract][Full Text] [Related]
14. Cyclophosphamide dose escalation in combination with vincristine and actinomycin-D (VAC) in gross residual sarcoma. A pilot study without hematopoietic growth factor support evaluating toxicity and response.
Ruymann FB; Vietti T; Gehan E; Wiener E; Wharam M; Newton WA; Maurer H
J Pediatr Hematol Oncol; 1995 Nov; 17(4):331-7. PubMed ID: 7583389
[TBL] [Abstract][Full Text] [Related]
15. Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group.
Casey DL; Chi YY; Donaldson SS; Hawkins DS; Tian J; Arndt CA; Rodeberg DA; Routh JC; Lautz TB; Gupta AA; Yock TI; Wolden SL
Cancer; 2019 Sep; 125(18):3242-3248. PubMed ID: 31174239
[TBL] [Abstract][Full Text] [Related]
16. Volumetric considerations in radiotherapy for pediatric parameningeal rhabdomyosarcomas.
Chen C; Shu HK; Goldwein JW; Womer RB; Maity A
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1294-9. PubMed ID: 12654440
[TBL] [Abstract][Full Text] [Related]
17. Soft tissue sarcomas arising in the retroperitoneal space in children. A report from the Intergroup Rhabdomyosarcoma Study (IRS) Committee.
Crist WM; Raney RB; Tefft M; Heyn R; Hays DM; Newton W; Beltangady M; Maurer HM
Cancer; 1985 Oct; 56(8):2125-32. PubMed ID: 3896467
[TBL] [Abstract][Full Text] [Related]
18. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803--a report from the Children's Oncology Group.
Lin C; Donaldson SS; Meza JL; Anderson JR; Lyden ER; Brown CK; Morano K; Laurie F; Arndt CA; Enke CA; Breneman JC
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1764-70. PubMed ID: 21470795
[TBL] [Abstract][Full Text] [Related]
19. Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide.
Casey DL; Wexler LH; Wolden SL
Int J Radiat Oncol Biol Phys; 2019 Apr; 103(5):1151-1157. PubMed ID: 30508617
[TBL] [Abstract][Full Text] [Related]
20. Perioperative intensity-modulated brachytherapy for refractory orbital rhabdomyosarcomas in children.
Strege RJ; Kovács G; Meyer JE; Holland D; Claviez A; Mehdorn MH;
Strahlenther Onkol; 2009 Dec; 185(12):789-98. PubMed ID: 20013088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
